Importer of Controlled Substances Application: ABBVIE LTD, 56994 [2017-25921]
Download as PDF
<![CDATA[
56994
ACTION:
Federal Register / Vol. 82, No. 230 / Friday, December 1, 2017 / Notices
Notice of application.
DEPARTMENT OF JUSTICE
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 30, 2018.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on August
11, 2017, Nanosyn, Inc., Nanoscale
Combinatorial Synthesis, 3331–B
Industrial Drive, Santa Rosa, California
95403 applied to be registered as a bulk
manufacturer for the basic classes of
controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Oxymorphone .................
Fentanyl ..........................
Drug
code
Schedule
9652
9801
II
II
sradovich on DSK3GMQ082PROD with NOTICES
The company is a contract
manufacturer. At the request of the
company’s customers, it manufactures
derivatives of controlled substances in
bulk form.
Dated: November 24, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–25916 Filed 11–30–17; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
16:44 Nov 30, 2017
Jkt 244001
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: ABBVIE LTD
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 2, 2018. Such persons
may also file a written request for a
hearing on the application on or before
January 2, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R
In accordance with 21 CFR
1301.34(a), this is notice that on October
27, 2016, ABBVIE, LTD, Carr. #2, KM
58.0 Cruce Davila, C/O PO Box 278,
Barceloneta, Puerto Rico 00617 applied
to be registered as an importer of
tapentadol (9780), a basic class of
controlled substance in schedule II.
The company plans to import an
intermediate form of tapentadol (9780)
to bulk manufacture tapentadol (9780)
DATES:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
for distribution to its customers.
Placement of this drug code onto the
company’s registration does not
translate into automatic approval of
subsequent permit applications to
import controlled substances. Approval
of permit applications will occur only
when the registrant’s business activity is
consistent with what is authorized
under 21 U.S.C 952(a)(2). Authorization
will not extend to the import of FDA
approved or non-approved finished
dosage forms for commercial sale.
Dated: November 24, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–25921 Filed 11–30–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1110–XXXX]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Approval of a
New Collection
Laboratory Division Federal
Bureau of Investigation Laboratory
Division Survey of Forensic Science
Services, Federal Bureau of
Investigation, Department of Justice.
ACTION: 60-Day Notice.
AGENCY:
The Department of Justice
(DOJ), Federal Bureau of Investigation
(FBI), Laboratory Division (LD) will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies.
DATES: Comments are encouraged and
will be accepted for 60 days until
January 30, 2018.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments,
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Cary Oien, United States Department of
Justice, Federal Bureau of Investigation,
Laboratory Division, 2501 Investigation
Parkway, Quantico, VA 22135
SUPPLEMENTARY INFORMATION: This
process is conducted in accordance with
5 CFR. Written comments and
suggestions from the public and affected
agencies concerning the proposed
collection of information are
encouraged. Your comments should
SUMMARY:
E:\FR\FM\01DEN1.SGM
01DEN1
]]>Agencies
[Federal Register Volume 82, Number 230 (Friday, December 1, 2017)]
[Notices]
[Page 56994]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25921]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: ABBVIE LTD
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before January 2, 2018.
Such persons may also file a written request for a hearing on the
application on or before January 2, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R
In accordance with 21 CFR 1301.34(a), this is notice that on
October 27, 2016, ABBVIE, LTD, Carr. #2, KM 58.0 Cruce Davila, C/O PO
Box 278, Barceloneta, Puerto Rico 00617 applied to be registered as an
importer of tapentadol (9780), a basic class of controlled substance in
schedule II.
The company plans to import an intermediate form of tapentadol
(9780) to bulk manufacture tapentadol (9780) for distribution to its
customers. Placement of this drug code onto the company's registration
does not translate into automatic approval of subsequent permit
applications to import controlled substances. Approval of permit
applications will occur only when the registrant's business activity is
consistent with what is authorized under 21 U.S.C 952(a)(2).
Authorization will not extend to the import of FDA approved or non-
approved finished dosage forms for commercial sale.
Dated: November 24, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-25921 Filed 11-30-17; 8:45 am]
BILLING CODE 4410-09-P
